Product Description
Serentrix is developing a rich clinical pipeline of innovative therapies that address pain associated with Dry Eye, Irritable Bowel Diseases, Acute pancreatitis and Vulvodynia using a TRPV1 receptor antagonist that is free of adverse events commonly seen in other compounds such as hyperthermia. (Sourced from: https://serentrix.com/pipeline/)
Mechanisms of Action: TRPV1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Serentrix
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|